Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.4K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.0K
Overview
83.0K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Replicative Cell Senescence02:15

Replicative Cell Senescence

4.2K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

mRNA-based MRI contrast agent for precise diagnosis of glioma and pseudoprogression.

Cell biomaterials·2026
Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026
Same author

Demonstration of Gliadin Penetration into the Epidermis by Tape Stripping as Prerequisite for Percutaneous Sensitisation in Wheat Allergy.

International journal of molecular sciences·2026
Same author

mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.

Nature biotechnology·2026
Same author

The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.

The Annals of thoracic surgery·2026
Same author

Dendritic Cell Heterogeneity Tailored to Their Function.

Immunological reviews·2026

関連する実験動画

Updated: Dec 24, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.3K

保存 さ れ た 樹突 細胞 調節 プログラム は,抗腫瘍 免疫 を 制限 する

Barbara Maier1,2,3, Andrew M Leader1,2,3, Steven T Chen1,2,3

  • 1The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Nature
|April 10, 2020
PubMed
まとめ
この要約は機械生成です。

研究 者 たち は,抗がん 免疫 療法 を 阻害 する 新しい 型 の 樹状 細胞 (DC) を 特定 し まし た. これらの成熟した免疫調節分子 (mregDCs) の特定のシグナル伝達経路を遮断することで,抗腫瘍免疫が回復し,腫瘍の成長が減少しました.

さらに関連する動画

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.3K

関連する実験動画

Last Updated: Dec 24, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.3K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.3K

科学分野:

  • 免疫学
  • 癌 生物学
  • 細胞生物学

背景:

  • チェックポイント・ブロック・セラピーは 癌治療に革命をもたらしましたが 多くの患者には効果がありません
  • 従来の1型 dendritic 細胞 (DC1s) は,CD8+ T 細胞の反応を初期化するために不可欠であり,がん生存率の向上と関連しています.
  • チェックポイント阻害に抵抗する腫瘍のDC1の存在は,これらの病変におけるDC機能の変化を示唆する.

研究 の 目的:

  • チェックポイント阻害に抵抗する腫瘍の樹状細胞 (DCs) の機能状態を調査する.
  • 新しいDCサブセットと,抗腫瘍免疫の調節におけるその役割を特定する.
  • 癌のDC機能不全の 分子メカニズムを解明するためです

主な方法:

  • 単細胞RNA配列解析は,ヒトとマウスの非小細胞肺がんのサンプルで実施した.
  • "免疫調節分子で濃縮された成熟型DC" (mregDCs) と呼ばれる,新たに特定されたDCサブセットの特徴.
  • Cd274 , Pdcd1lg2 , Cd200 , Cd40 , Ccr7 , Il12b を含む免疫調節と成熟に関連する遺伝子発現の分析

主要な成果:

  • 免疫調節および成熟遺伝子を共発する新しいDCサブセットであるmregDCsが特定されました.
  • mregDCプログラムは,腫瘍抗原の吸収時に従来のDC1およびDC2で誘導されます.
  • mregDCsにおけるプログラム死亡リガンド1のアップレギュレーションはAXLに依存し,IL-12の生成はIL-4シグナリングによってネガティブに調節される.
  • IL- 4を阻害すると,mregDC1によるIL- 12の産生が増加し,エフェクターT細胞が増加し,腫瘍の負荷が減少した.

結論:

  • 腫瘍抗原吸収に関連した調節モジュールは,がんにおけるDC1の機能を損なう.
  • mregDCsのIL-4信号経路をターゲットにすることで,抗腫瘍免疫を回復させることができます.
  • これらの発見は,がんの免疫療法の有効性を向上させるための新たな戦略を提供している.